Breaking News Instant updates and real-time market news.

BR

Broadridge

$66.89

0.95 (1.44%)

, CME

CME Group

$112.67

0.79 (0.71%)

07:54
11/30/16
11/30
07:54
11/30/16
07:54

JPMorgan to hold a forum

Fintech & Specialty Finance Forum is being held in New York on November 30 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

BR

Broadridge

$66.89

0.95 (1.44%)

CME

CME Group

$112.67

0.79 (0.71%)

BKFS

Black Knight Financial

$37.25

-0.3 (-0.80%)

DFS

Discover

$67.62

-0.13 (-0.19%)

KCG

KCG Holdings

$14.52

-0.21 (-1.43%)

NAVI

Navient

$17.19

-0.3 (-1.72%)

OMF

OneMain Holdings

$19.66

-0.23 (-1.16%)

GDOT

Green Dot

$24.18

0.05 (0.21%)

ESNT

Essent Group

$30.58

0.58 (1.93%)

SLM

Sallie Mae

$9.75

0.08 (0.83%)

NMIH

NMI Holdings

ONDK

On Deck Capital

$4.61

-0.06 (-1.28%)

  • 30

    Nov

  • 02

    Dec

  • 06

    Dec

BR Broadridge
$66.89

0.95 (1.44%)

11/28/16
MSCO
11/28/16
NO CHANGE
MSCO
Softline Black Friday weekend sales mixed versus last year, says Morgan Stanley
Morgan Stanley said overall Softline Black Friday weekend sales were mixed verus last year saying L Brands (LB), lululemon (LULU), and Hollister were weekend winners and Gap (GPS), Broadridge (BR), Michael Kors (KORS), and Anthro were laggards.
09/13/16
ATLE
09/13/16
INITIATION
Target $82
ATLE
Overweight
Broadridge initiated with an Overweight at Atlantic Equities
Atlantic Equities analyst Jennifer Cook initiated Broadridge with an Overweight and an $82 price target.Target $82.
09/29/16
SDLR
09/29/16
DOWNGRADE
SDLR
Hold
Broadridge downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Christopher Donat downgraded Broadridge to Hold based on valuation.
11/04/16
11/04/16
NO CHANGE

Broadridge acquires M&O Systems
Broadridge Financial acquired M&O Systems, a provider of advisor compensation management solutions that help broker-dealers and wealth management firms support advisors and grow their businesses. Terms of the deal were not disclosed. With this acquisition, Broadridge expands its wealth offerings to include advisor compensation and incentive management, advisor commission portal, account opening and client books and records solutions. M&O Systems will be rebranded as Broadridge Advisor Compensation solutions.
CME CME Group
$112.67

0.79 (0.71%)

09/23/16
RBCM
09/23/16
NO CHANGE
RBCM
CBOE 'likely in the cross-hairs' of bigger peers, says RBC Capital
RBC Capital analyst Andrew Bond said he thinks the strategic risk of a deal whereby CBOE (CBOE) buys Bats Global Markets (BATS), as it has been reported to be in talks to do, outweighs the potential reward. However, he also believe CBOE's relatively small size, limited regulatory risk, clean balance sheet, and strong organic growth make it an attractive target for its largest exchange peers, such as IntercontinentalExchange (ICE) and CME Group (CME). A combined CBOE/BATS would be more difficult to acquire, so if CBOE is to be acquired, "the time is now," added Bond.
11/14/16
JPMS
11/14/16
DOWNGRADE
Target $116
JPMS
Neutral
CME Group downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Kenneth Worthington downgraded CME Group to Neutral citing valuation with the stock near his unchanged price target of $116. The current strong volumes are now priced into the stock and create very tough comps for 2017, Worthington tells investors in a research note.
09/12/16
JPMS
09/12/16
NO CHANGE
Target $116
JPMS
Overweight
CME Group price target raised to $116 from $106 at JPMorgan
JPMorgan analyst Kenneth Worthington raised his price target for CME Group to $116 saying the company's product mix benefits from the current market environment. The analyst sees further share upside and keeps an Overweight rating on CME.
08/31/16
JEFF
08/31/16
NO CHANGE
Target $118
JEFF
Buy
CME Group price target raised to $118 from $112 at Jefferies
Jefferies analyst Daniel Fannon raised his price target for CME Group to $118 after traveling with management. The analyst says the diversity of CME's growth continues and he keeps a Buy rating on the shares.
BKFS Black Knight Financial
$37.25

-0.3 (-0.80%)

09/19/16
KBWI
09/19/16
UPGRADE
Target $46
KBWI
Outperform
Black Knight Financial upgraded to Outperform at Keefe Bruyette
Keefe Bruyette upgraded Black Knight Financial to Outperform from Market Perform after transferring coverage to analyst Chas Tyson. The company has "numerous growth opportunities" to drive revenue and EBITDA growth at high-single to low-double-digit rates over the medium term, Tyson tells investors in a research note. He raised his price target for the shares to $46 from $38.
06/24/16
WELS
06/24/16
NO CHANGE
WELS
Black Knight Financial has reached attractive entry point, says Wells Fargo
Wells Fargo believes that Black Knight's stock (BKFS) was sold on the news of its contract with Bank of America (BAC). The firm says that the deal shows that Black Knight is paused to capitalize on banks' demand for solutions that lower their costs and regulatory risk. It believes that the decline in Black Knight's stock has created a good entry point for longer term investors, and it keeps an Outperform rating on the shares.
07/21/16
07/21/16
NO CHANGE

Black Knight Financial price target raised to $47 from $39 at SunTrust
After Black Knight provided fiscal 2016 EPS guidance whose midpoint was well above the consensus outlook, SunTrust thinks that the company is nearing a positive turning point. The firm thinks that the company is well-positioned to increase its market share. It keeps a Buy rating on the stock.
07/21/16
MONN
07/21/16
DOWNGRADE
Target $32
MONN
Sell
Black Knight Financial downgraded to Sell from Neutral at Monness Crespi
Monness Crespi analyst Alexander Veytsman downgraded earlier today Black Knight Financial to Sell saying the company's revenue is likely to decelerate in 2017. The analyst has a $32 price target for the shares.
DFS Discover
$67.62

-0.13 (-0.19%)

11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
11/18/16
INITIATION
Target $40

Overweight
Synchrony initiated with an Overweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Synchrony (SYF) with an Overweight rating and $40 price target, citing $5B excess capital that allows Synchrony to buy back 20% of company once capital return is deregulated, industry retail share weakness, and revenue growth. The analyst also started American Express (AXP) and Discover (DFS) with an Underweight rating.
11/18/16
11/18/16
INITIATION
Target $62

Underweight
Discover initiated with an Underweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Discover (DFS) with an Underweight rating and $62 price target, citing shrinking margins as American Express (AXP) ramps up rewards to maintain share, credit costs normalizing higher likely making Discover's shares range bound, and personal lending competition. The analyst also started American Express with an Underweight rating.
11/18/16
SPHN
11/18/16
INITIATION
Target $62
SPHN
Underweight
Discover initiated with an Underweight at Stephens
Stephens analyst Vincent Caintic started Discover with an Underweight rating and $62 price target.
KCG KCG Holdings
$14.52

-0.21 (-1.43%)

07/14/16
07/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) upgraded to Buy from Neutral at UBS with analyst Stephen Powers saying the risk/reward is positive given the company's changes over the past six months. 2. Dick's Sporting (DKS) upgraded to Outperform from Sector Perform at RBC Capital with the firm saying it thinks that the company has a number of potential positive catalysts going forward, including reduced disruption from the Sports Authority's liquidation in the second quarter and third quarter and potential benefits from the liquidation next year, along with reduced spending on e-commerce in 2017. 3. GlaxoSmithKline (GSK) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying fears of a dividend cut are overdone and the company's improving yield quality will continue to attract investors. 4. Southern Company (SO) upgraded to Overweight from Equal Weight at Barclays with analyst Daniel Ford saying the risk/reward is improving as it transforms to an infrastructure company. 5. Barrick Gold (ABX) and Randgold (GOLD) upgraded to Buy from Hold and Kinross Gold (KGC) upgraded to Hold from Underperform at Jefferies with analyst Christopher LaFemina upgrading the stocks after his firm increased its gold price forecasts to reflect ongoing elevated macro risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/16
BUCK
06/07/16
INITIATION
Target $17
BUCK
Buy
KCG Holdings initiated with a Buy at Buckingham
Target $17.
NAVI Navient
$17.19

-0.3 (-1.72%)

12/29/15
JPMS
12/29/15
NO CHANGE
JPMS
Overweight
Navient selloff yesterday an overreaction, says JPMorgan
JPMorgan analyst Richard Shane views yesterday's 9% pullback in shares of Navient as an overreaction. The reduction in the company's credit facility through Federal Home Loan Bank of Des Moines is likely to have little practical impact, Shane tells investors in a research note. Navient indicated that no loans need to be moved or sold as a result of the change, the analyst points out. He keeps an Overweight rating on Navient.
07/20/16
GSCO
07/20/16
DOWNGRADE
Target $15
GSCO
Neutral
Navient downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Eric Beardsley downgraded Navient to Neutral saying the risk/reward is more balanced at current share levels. The analyst keeps a $15 price target for the stock.
12/28/15
JANY
12/28/15
NO CHANGE
Target $17
JANY
Buy
Navient borrowing cut makes FFELP loan buying tougher, says Janney Capital
Janney Capital analyst Sameer Gokhale said Navient having its borrowing facility reduced makes acquiring smaller FFELP loan portfolios more challenging and trimmed his fair value estimate on the stock to $17 from $18 to account for the news. Gokhale keeps a Buy rating on Navient shares.
07/21/16
07/21/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Navient (NAVI) downgraded to Neutral from Buy at Goldman with analyst Eric Beardsley saying the risk/reward is more balanced at current share levels. 2. Ericsson (ERIC) downgraded to Neutral from Buy at UBS with the firm citing a lack of revenue stabilization in the second quarter and little management commentary stating it would change. 3. Graco (GGG) downgraded to Market Perform from Outperform at William Blair with analyst Nicholas Heymann citing the company's transition after it cut its fiscal 2016 organic growth view. 4. ASML (ASML) downgraded to Neutral from Buy at UBS with analyst Gareth Jenkins stating he thinks ASML shares are now discounting some of the recent positive developments on EUV lithography following a 28% rally since January. 5. Boardwalk Pipeline (BWP) downgraded to Neutral from Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OMF OneMain Holdings
$19.66

-0.23 (-1.16%)

11/10/16
LEHM
11/10/16
DOWNGRADE
Target $19
LEHM
Equal Weight
OneMain Holdings downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Mark DeVries downgraded OneMain Holdings to Equal Weight saying he doesn't like the risk/reward profile despite the post-earnings selloff. The company's 2017 outlook implies core earnings that are approximately 34% lower than previous guidance, the analyst notes. He cut his price target for the shares to $19 from $36.
11/08/16
11/08/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hertz (HTZ) downgraded to Hold from Buy at Deutsche Bank and to Neutral from Buy at Northcoast. 2. AT&T (T) downgraded to Perform from Outperform at Oppenheimer with analyst Timothy Horan saying CenturyLink's (CTL) dividend is "relatively more attractive." 3. Bank of America (BAC) and Citizens Financial (CFG) downgraded to Hold from Buy at Deutsche Bank. 4. OneMain (OMF) downgraded to Market Perform from Outperform at Keefe Bruyette, to Neutral from Buy at Guggenheim, to Underperform from Buy at BofA/Merrill, to Neutral from Buy at Janney Capital, to Market Perform from Outperform at FBR Capital, and to Neutral from Outperform at Wedbush. 5. KeyCorp (KEY) and Goldman Sachs (GS) downgraded to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/16
SBSH
11/08/16
DOWNGRADE
Target $21
SBSH
Neutral
OneMain Holdings downgraded to Neutral from Buy at Citi
Citi analyst Donald Fandetti downgraded OneMain Holdings to Neutral saying concerns around integration challenges and credit fears will weigh on the shares. The analyst cut his price target for the stock to $21 from $34.
11/08/16
SPHN
11/08/16
NO CHANGE
Target $27
SPHN
Equal Weight
OneMain Holdings price target lowered to $27 from $37 at Stephens
Stephens analyst Vincent Caintic lowered his price target for OneMain Holdings to $27 from $37 as he is incrementally more negative on its shares after Q3 earnings results. The analyst recommends not buying OneMain Holdings even on moderate weakness to shares post-earnings as he believes shares have no upside catalysts through 2017. Caintic reiterates an Equal Weight rating on the shares.
GDOT Green Dot
$24.18

0.05 (0.21%)

02/24/16
02/24/16
NO CHANGE

Green Dot reports Q4 non-GAAP EPS 6c, consensus 3c
Reports Q4 non-GAAP revenue $151.0M, consensus $149.49M.
03/04/16
NORL
03/04/16
INITIATION
Target $28
NORL
Outperform
Green Dot initiated with an Outperform at Northland
Northland analyst Mike Grondahl started Green Dot with an Outperform rating and $28 price target.
03/18/16
BTIG
03/18/16
DOWNGRADE
BTIG
Neutral
Green Dot downgraded to Neutral from Buy at BTIG
03/18/16
BTIG
03/18/16
DOWNGRADE
BTIG
Neutral
Green Dot downgraded to Neutral on valuation at BTIG
As previously reported, BTIG downgraded Green Dot to Neutral from Buy. Analyst Mark Palmer downgraded shares following the achievement of his $23 price target.
ESNT Essent Group
$30.58

0.58 (1.93%)

08/05/16
KBWI
08/05/16
DOWNGRADE
Target $26.5
KBWI
Market Perform
Essent Group downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Bose George downgraded Essent Group to Market Perform citing valuation following the company's Q2 results. The analyst raised his price target for the shares to $26.50 from $26.
10/27/16
BOFA
10/27/16
DOWNGRADE
BOFA
Underperform
Essent Group downgraded to Underperform from Neutral at BofA/Merrill
10/27/16
10/27/16
DOWNGRADE
Target $29

Underperform
Essent Group downgraded to Underperform on valuation at BofA/Merrill
BofA/Merrill transferred coverage on Essent Group to Mihir Bhatia who downgraded shares to Underperform from Neutral while maintaining a $29 price target. The analyst sees limited upside given Essent's premium valuation to peers and lack of near-term earnings catalysts.
09/28/16
BOFA
09/28/16
DOWNGRADE
BOFA
Neutral
Essent Group downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Essent Group to Neutral due to recent share gains.
SLM Sallie Mae
$9.75

0.08 (0.83%)

03/22/16
03/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ferrellgas Partners LP (FGP) initiated with a Neutral at Janney Capital by analyst Nathan Judge, who said valuation offsets lack of growth distribution. 2. Monster Beverage (MNST) initiated with a Neutral at BofA/Merrill given shares trade at a premium valuation. 3. Sallie Mae (SLM) initiated with a Buy at DA Davidson by analyst Arren Cyganovich, who believes shares are undervalued given SLM's dominant market position and expected growth. 4. West Pharmaceutical (WST) initiated with an Outperform at Wells Fargo with analyst Tim Evans believing that injectables will grow at twice the rate of small molecule drugs over the next five years. He calls West the dominant manufacturer of critical components for the packaging and delivery of complex injectables. 5. Avis Budget (CAR) initiated with a Buy at Sterne Agee CRT. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/16
GSCO
08/10/16
UPGRADE
Target $9
GSCO
Conviction Buy
Sallie Mae upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Eric Beardsley added Sallie Mae to the Conviction Buy List given high visibility into its 20%+ EPS CAGR and 15%+ ROE. Following Q2 results, the analyst has increased confidence in earnings given better than expected charge off trends and the first ever CFPB review was positive with no action times for the company. Berdsley has a 9 price target on Sallie Mae shares.
07/14/16
07/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ball Corp. (BLL) reinstated with an Equal Weight at Barclays. 2. Southern Company (SO) initiated with a Neutral at Goldman. 3. Achillion (ACHN) initiated with a Sell on lack of data, competition at Chardan. 4. Sallie Mae (SLM) initiated with a Buy at Citi. 5. Vocera (VCRA) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/14/16
SBSH
07/14/16
INITIATION
Target $8.5
SBSH
Buy
Sallie Mae initiated with a Buy at Citi
Citi analyst Michael Kaye started Sallie Mae with a Buy rating and $8.50 price target. The company is a "a rarity" among financial stocks since it has "strong" earnings growth and is not dependent on rising interest rates, Kaye tells investors in a research note.
NMIH NMI Holdings

04/27/16
ZELM
04/27/16
UPGRADE
ZELM
Buy
NMI Holdings upgraded to Buy from Hold at Zelman
ONDK On Deck Capital
$4.61

-0.06 (-1.28%)

08/03/16
OPCO
08/03/16
INITIATION
OPCO
Perform
On Deck Capital initiated with a Perform at Oppenheimer
Oppenheimer analyst Jed Kelly initiated On Deck Capital with a Perform rating saying valuation support will be challenged given his outlook for a lower Marketplace-loan mix, and competition-limiting near-term S&M leverage.
07/25/16
ADAM
07/25/16
NO CHANGE
ADAM
Online lending stocks should continue to see headwinds in Q2, says Canaccord
Canaccord believes the online lending stocks are likely to face headwinds through Q2 earnings as investors continue to be concerned about credit risk, investors demand for loans, regulatory action, and layoffs. The firm believes the companies' models hold promise and the public companies should benefit from the tougher capital raising environment for private players. Canaccord maintains its Hold rating on both Lending club (LC) and On Deck Capital (ONDK).
09/20/16
GUGG
09/20/16
INITIATION
GUGG
Neutral
On Deck Capital initiated with a Neutral at Guggenheim
08/09/16
STFL
08/09/16
NO CHANGE
STFL
On Deck Capital reported 'solid' results, says Stifel
Stifel analyst Christopher Brendler believes that On Deck reported "solid" Q2 results in a "tough environment." The analyst continues to believe that the company's diversified funding model is a "key differentiator" that increases its flexibility and he says that the stock's valuation is attractive, in light of the company's growth rate. He cut his price target on the shares to $7 from $10 but reiterates a Buy rating.

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.